Literature DB >> 24631106

Predictors of unfavorable disease after radical prostatectomy in patients at low risk by D'Amico criteria: role of multiparametric magnetic resonance imaging.

Sang Hoon Song1, Sahyun Pak1, Sejun Park1, Cheryn Song1, In Gab Jeong1, Hyuk Jae Choi1, Jeong Kon Kim1, Kyoung-Sik Cho1, Choung-Soo Kim1, Hanjong Ahn2.   

Abstract

PURPOSE: We identified risk factors predicting unfavorable pathological outcomes after radical prostatectomy in patients with low risk prostate cancer. We also evaluated the role of magnetic resonance imaging.
MATERIALS AND METHODS: We retrospectively reviewed the medical records of 1,262 patients who underwent 12-core biopsy, preoperative magnetic resonance imaging and radical prostatectomy at a single center between September 2007 and June 2012. A total of 382 men with low risk prostate cancer by the D'Amico criteria were included in study. Multivariate logistic regression analysis was used to identify factors predicting unfavorable pathological outcomes.
RESULTS: Median patient age was 65 years and median preoperative prostate specific antigen was 4.6 ng/ml. Gleason sum was upgraded in 212 patients (55.5%). In 249 patients (65.1%) prostate cancer was identified on 3 Tesla T2-weighted and diffusion-weighted magnetic resonance imaging without dynamic contrast imaging. The lesion was in the anterior and posterior of the prostate in 42.9% and 57.0% of cases, respectively. Unfavorable pathological results were found postoperatively in 29.6% of patients. Multivariate analysis revealed that older age (OR 1.072, p<0.001), number of positive cores (OR 1.373, p<0.001) and an anterior index tumor site on magnetic resonance imaging (OR 2.121, p=0.017) were significant predictors of unfavorable final pathological results (pT3 or greater, or tumor upgrading to Gleason 3+4 plus tumor volume 15% or greater, or upgrading to Gleason 4+3 or greater).
CONCLUSIONS: An anterior site of cancer on magnetic resonance imaging was useful for predicting Gleason sum upgrading or an unfavorable pathological outcome after radical prostatectomy in patients with low risk prostate cancer.
Copyright © 2014 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  magnetic resonance imaging; neoplasm grading; prostate; prostatectomy; prostatic neoplasms

Mesh:

Year:  2014        PMID: 24631106     DOI: 10.1016/j.juro.2014.02.2568

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  5 in total

1.  The significance of anterior prostate lesions on multiparametric magnetic resonance imaging in African-American men.

Authors:  Michael Kongnyuy; Abhinav Sidana; Arvin K George; Akhil Muthigi; Amogh Iyer; Michele Fascelli; Meet Kadakia; Thomas P Frye; Richard Ho; Francesca Mertan; M Minhaj Siddiqui; Daniel Su; Maria J Merino; Baris Turkbey; Peter L Choyke; Bradford J Wood; Peter A Pinto
Journal:  Urol Oncol       Date:  2016-02-20       Impact factor: 3.498

2.  Can contemporary patients with biopsy Gleason score 3+4 be eligible for active surveillance?

Authors:  Ohseong Kwon; Tae Jin Kim; In Jae Lee; Seok-Soo Byun; Sang Eun Lee; Sung Kyu Hong
Journal:  PLoS One       Date:  2014-09-30       Impact factor: 3.240

3.  Intraprostatic locations of tumor foci of higher grade missed by diagnostic prostate biopsy among potential candidates for active surveillance.

Authors:  Kwangmo Kim; Jung Keun Lee; Gheeyoung Choe; Sung Kyu Hong
Journal:  Sci Rep       Date:  2016-11-09       Impact factor: 4.379

Review 4.  Multi-parametric magnetic resonance imaging as a management decision tool.

Authors:  David C Johnson; Robert E Reiter
Journal:  Transl Androl Urol       Date:  2017-06

5.  Prognostic value of seminal vesicle invasion on preoperative multi-parametric magnetic resonance imaging in pathological stage T3b prostate cancer.

Authors:  Jung Kwon Kim; Hak Jong Lee; Sung Il Hwang; Gheeyoung Choe; Sung Kyu Hong
Journal:  Sci Rep       Date:  2020-03-30       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.